|
US4229447A
(en)
|
1979-06-04 |
1980-10-21 |
American Home Products Corporation |
Intraoral methods of using benzodiazepines
|
|
IE56702B1
(en)
|
1982-12-01 |
1991-11-06 |
Usv Pharma Corp |
Antiinflammatory antiallergic compounds
|
|
US4596795A
(en)
|
1984-04-25 |
1986-06-24 |
The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services |
Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
|
|
US4755386A
(en)
|
1986-01-22 |
1988-07-05 |
Schering Corporation |
Buccal formulation
|
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
|
US5739136A
(en)
|
1989-10-17 |
1998-04-14 |
Ellinwood, Jr.; Everett H. |
Intraoral dosing method of administering medicaments
|
|
US5563143A
(en)
|
1994-09-21 |
1996-10-08 |
Pfizer Inc. |
Catechol diether compounds as inhibitors of TNF release
|
|
US7067664B1
(en)
|
1995-06-06 |
2006-06-27 |
Pfizer Inc. |
Corticotropin releasing factor antagonists
|
|
US6956047B1
(en)
|
1995-06-06 |
2005-10-18 |
Pfizer Inc. |
Corticotropin releasing factor antagonists
|
|
US6632823B1
(en)
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
|
HUP0204272A3
(en)
|
2000-01-18 |
2005-03-29 |
Pfizer Prod Inc |
Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use
|
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US20030134836A1
(en)
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
|
FI20030030A0
(fi)
|
2003-01-09 |
2003-01-09 |
Orion Corp |
Uusia yhdisteitä
|
|
MXPA05012459A
(es)
|
2003-05-19 |
2006-02-22 |
Irm Llc |
Compuestos y composiciones inmunosupresoras.
|
|
WO2007016784A1
(en)
|
2005-08-11 |
2007-02-15 |
Merck Frosst Canada Ltd. |
Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors
|
|
EP1715868A1
(en)
|
2004-01-29 |
2006-11-02 |
Pfizer Products Incorporated |
Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
|
|
EP1727788B1
(en)
|
2004-03-12 |
2010-07-28 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
CA2557794A1
(en)
|
2004-03-15 |
2005-10-06 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
ZA200609259B
(en)
|
2004-04-30 |
2008-07-30 |
Takeda Pharmaceutical |
Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
|
|
US7507748B2
(en)
|
2004-07-22 |
2009-03-24 |
Amgen Inc. |
Substituted aryl-amine derivatives and methods of use
|
|
MX2007002842A
(es)
|
2004-09-10 |
2007-04-30 |
Pfizer Prod Inc |
Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol.
|
|
EP1791541A2
(en)
|
2004-09-10 |
2007-06-06 |
Pfizer Products Inc. |
Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds
|
|
EP1807417A2
(en)
|
2004-11-04 |
2007-07-18 |
Neurogen Corporation |
Pyrazolylmethyl heteroaryl derivatives
|
|
DE102004056226A1
(de)
|
2004-11-22 |
2006-05-24 |
Burchardt, Elmar Reinhold, Dr.Dr. |
Neuartige Inhibitoren der Lysyloxidase
|
|
EP1846379B1
(en)
|
2005-01-31 |
2009-08-19 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
AR055041A1
(es)
|
2005-03-23 |
2007-08-01 |
Merck Frosst Canada Ltd |
Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
|
|
US7405302B2
(en)
|
2005-10-11 |
2008-07-29 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
|
ITMI20051943A1
(it)
|
2005-10-14 |
2007-04-15 |
Procos Spa |
Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi
|
|
US20070225285A1
(en)
|
2005-11-04 |
2007-09-27 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
|
US20070219206A1
(en)
|
2005-11-04 |
2007-09-20 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
|
EP1978966A4
(en)
|
2006-01-23 |
2010-11-10 |
Amira Pharmaceuticals Inc |
TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
|
|
GB0614579D0
(en)
|
2006-07-21 |
2006-08-30 |
Black James Foundation |
Pyrimidine derivatives
|
|
JP2010501553A
(ja)
|
2006-08-18 |
2010-01-21 |
アストラゼネカ アクチボラグ |
Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
|
|
IL184627A0
(en)
|
2007-07-15 |
2008-12-29 |
Technion Res & Dev Foundation |
Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
|
|
ES2700141T3
(es)
|
2007-08-02 |
2019-02-14 |
Gilead Biologics Inc |
Anticuerpos inhibidores LOXL2 y usos de los mismos
|
|
MX2012001156A
(es)
|
2009-07-28 |
2012-05-08 |
Anacor Pharmaceuticals Inc |
Moleculas que contienen boro trisustituidas.
|
|
BR112012008084A2
(pt)
|
2009-08-21 |
2019-09-24 |
Gilead Biologics Inc |
método terapêuticos e composições.
|
|
BR112012019693A2
(pt)
|
2010-02-04 |
2017-06-20 |
Gilead Biologics Inc |
anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
|
|
EP2542089B1
(en)
|
2010-03-05 |
2017-01-18 |
Karyopharm Therapeutics, Inc. |
Nuclear transport modulators and uses thereof
|
|
PE20140146A1
(es)
*
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
JP6073343B2
(ja)
|
2011-10-20 |
2017-02-01 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
|
|
IN2014MN01982A
(https=)
|
2012-04-25 |
2015-07-10 |
Raqualia Pharma Inc |
|
|
SG11201503065PA
(en)
|
2012-10-30 |
2015-05-28 |
Gilead Sciences Inc |
Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
|
|
JP6301842B2
(ja)
|
2012-12-18 |
2018-03-28 |
Ｅａファーマ株式会社 |
複素環アミド誘導体及びそれを含有する医薬
|
|
WO2016020732A1
(en)
|
2014-08-05 |
2016-02-11 |
The University Of British Columbia |
Modulators of caspase-6
|
|
US9051320B1
(en)
|
2014-08-18 |
2015-06-09 |
Pharmakea, Inc. |
Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
|
|
JP6700291B2
(ja)
|
2015-02-15 |
2020-05-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
１−（ｈｅｔ）アリールスルホニル−（ピロリジン又はピペリジン）−２−カルボキサミド誘導体、及びｔｒｐａ１拮抗薬としてのそれらの使用
|
|
AU2016229268B2
(en)
*
|
2015-03-06 |
2020-09-10 |
Pharmakea, Inc. |
Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
|
|
EP3265445B1
(en)
|
2015-03-06 |
2021-05-05 |
Pharmakea, Inc. |
Lysyl oxidase-like 2 inhibitors and uses thereof
|
|
CA3036064A1
(en)
*
|
2016-09-07 |
2018-03-15 |
Pharmakea, Inc. |
Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
|
|
WO2018048942A1
(en)
|
2016-09-07 |
2018-03-15 |
Pharmakea, Inc. |
Uses of a lysyl oxidase-like 2 inhibitor
|